Ambulero

Ambulero is a private, preclinical-stage biotechnology company leveraging a novel platform based on the therapeutic delivery of E-selectin to combat vascular disease. The company is advancing two core modalities: engineered 'supercharged' mesenchymal stromal cells (MSCs) and an AAV-based gene therapy, both designed to stimulate blood vessel growth and tissue repair. Initially targeting a rare form of vascular ischemia with high unmet need, Ambulero's technology is built on over a decade of NIH-funded academic research from its scientific founders. The company is led by a team with experience in entrepreneurship, drug development, and vascular surgery.

Dual-platform focused on delivering the E-selectin molecule via engineered 'supercharged' mesenchymal stromal cells (MSCs) or an AAV-based gene therapy vector to stimulate angiogenesis and tissue repair.

The field of regenerative therapies for vascular disease includes companies developing stem cell therapies, gene therapies, and growth factor-based approaches. Ambulero's specific focus on E-selectin as a therapeutic agent appears novel, differentiating it from competitors targeting VEGF or other angiogenic pathways. However, it must compete for funding and clinical validation in a crowded therapeutic space.